| NCT ID | NCT05534971 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Montefiore Medical Center |
| Condition | Shock |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2022-11-16 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 160 participants in total. It began in 2022-11-16 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Two different techniques for placing a central venous catheter will be compared. The studyu team hypothesizes that clinicians randomized to the peripheral catheter technique will have higher first attempt success rates, fewer procedural complications, and a shorter mean time to procedure completion than physicians assigned to wire through hollow bore needle.
Eligibility Criteria
Inclusion Criteria: Adult patients in the emergency department who require ultrasound guided central line placement are eligible for participation and will be referred for participation in the study by the clinical team. Exclusion Criteria: * Inherited, acquired, or medication related coagulopathy or thrombocytopenia (platelets \< 100,000). Patients will not be excluded for use of aspirin or other anti-platelet medication. * Previous central venous access at the same anatomical site. * Any indwelling catheter or wire that could potentially interfere with central line placement * Anterior border of the target vein deeper than 3.5cm Or for any clinical feature that would interfere with obtaining informed consent including dementia, delirium, or encephalopathy, as determined by the clinical attending physician.
Contact & Investigator
Benjamin J Friedman, MD
PRINCIPAL INVESTIGATOR
Montefiore Medical Center
Frequently Asked Questions
Who can join the NCT05534971 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05534971 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05534971 currently recruiting?
Yes, NCT05534971 is actively recruiting participants. Contact the research team at joseph.offenbacher@nyulangone.org for enrollment information.
Where is the NCT05534971 trial being conducted?
This trial is being conducted at The Bronx, United States.
Who is sponsoring the NCT05534971 clinical trial?
NCT05534971 is sponsored by Montefiore Medical Center. The principal investigator is Benjamin J Friedman, MD at Montefiore Medical Center. The trial plans to enroll 160 participants.